58 terminated. 58 Phase 2, 19 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 58 | Terminated 58 |
| Phase 1 | 19 | Terminated 19 |
| Phase 3 | 1 | Terminated 1 |
Follow Fallopian Tube Diseases: new trials by email Literature Review of Fallopian Tube Diseases trials Research Report on Fallopian Tube Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors INCB099280, axitinib - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 5 | 2024-04-16 | 2026-06-04 |
| REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 2 / Phase 3 | Terminated | Sutro Biopharma, Inc. | 600 | 2023-07-12 | 2025-09-23 |
| A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD) - Neoplasms, Ovarian | Phase 2 | Terminated | Bristol-Myers Squibb | 106 | 2023-02-01 | 2026-10-28 |
| A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary AVB-001 (Dose Escalation Phase), AVB-001 (Dose Expansion Phase) - Neoplasm, Ovarian, Fallopian Tube Cancer | Phase 1 / Phase 2 | Terminated | Avenge Bio, Inc | 14 | 2022-12-09 | 2024-04-24 |
| Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer maplirpacept (PF-07901801), Pegylated Liposomal Doxorubicin (PLD) - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Pfizer | 10 | 2022-08-01 | 2024-11-19 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) ELU001 - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Elucida Oncology | 79 | 2021-09-13 | 2024-08-07 |
| A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD) - Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Terminated | THERAPIM PTY LTD | 16 | 2021-09-01 | 2024-02-14 |
| T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer Ipilimumab, Cyclophosphamid, Fludarabine Phosphate - Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer | Phase 1 / Phase 2 | Terminated | Inge Marie Svane | 6 | 2021-04-22 | 2025-08-12 |
| A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors NM21-1480 - Advanced Solid Tumor, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Numab Therapeutics AG | 52 | 2020-08-19 | 2025-05-23 |
| A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes Rucaparib - Solid Tumor | Phase 2 | Terminated | pharmaand GmbH | 83 | 2020-01-16 | 2023-10-02 |
| AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Batiraxcept, Durvalumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 12 | 2019-12-03 | 2025-06-11 |
| Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer) Niraparib - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Terminated | Mario Negri Institute for Pharmacological Research | 83 | 2019-11-13 | 2025-01-17 |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) Rucaparib, Nivolumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Terminated | pharmaand GmbH | 1 | 2019-08-23 | 2023-06-12 |
| A Study of PF-06873600 in People With Cancer PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2 - HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer | Phase 1 / Phase 2 | Terminated | Pfizer | 155 | 2018-03-07 | 2025-11-14 |
| A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab - Renal Cell Carcinoma (RCC), Urothelial Carcinoma | Phase 1 / Phase 2 | Terminated | Sumitomo Pharma America, Inc. | 47 | 2017-12-14 | 2024-04-18 |
| Anti-PD-L1 and SAbR for Ovarian Cancer Avelumab - Recurrent Epithelial Cancer of Ovary, Primary Peritoneal Carcinoma | Phase 2 | Terminated | University of Texas Southwestern Medical Center | 5 | 2017-11-09 | 2020-11-12 |
| Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2017-11-08 | 2026-10-20 |
| Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2017-05-05 | 2024-03-13 |
| IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery Carboplatin, Gynecological Surgical Procedure, Laboratory Biomarker Analysis - Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer | Phase 2 | Terminated | University of Washington | 11 | 2017-04-03 | 2022-01-14 |
| Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). Pembrolizumab, Paclitaxel, Carboplatin - Fallopian Tube Cancer, Peritoneum Cancer | Phase 2 | Terminated | University of Miami | 26 | 2016-12-22 | 2023-11-07 |
Showing 20 of 58. Sign in to see all of them.
Fallopian Tube Neoplasms (58) · Ovarian Neoplasms (50) · Carcinoma, Ovarian Epithelial (24) · Endometrial Neoplasms (3) · Uterine Cervical Neoplasms (3) · Breast Neoplasms (2) · Brenner Tumor (2) · Carcinoma (2) · Carcinoma, Endometrioid (2) · Carcinosarcoma (2) · Colorectal Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Peritoneal Neoplasms (2) · Recurrence (2)
Adnexal Diseases (58) · Female Urogenital Diseases (58) · Female Urogenital Diseases and Pregnancy Complications (58) · Genital Diseases (58) · Genital Diseases, Female (58) · Genital Neoplasms, Female (58) · Neoplasms by Site (58) · Urogenital Diseases (58) · Urogenital Neoplasms (58) · Endocrine Gland Neoplasms (57) · Endocrine System Diseases (57) · Gonadal Disorders (57) · Neoplasms (56) · Ovarian Diseases (56)
Paclitaxel (14) · Carboplatin (10) · liposomal doxorubicin (8) · Bevacizumab (6) · Gemcitabine (5) · Taxes (5) · Cisplatin (4) · Topotecan (4) · Disulfides (3) · Immunoglobulin G (3) · Nivolumab (3) · Cyclophosphamide (2) · Doxorubicin (2) · Oxaliplatin (2) · STA 9090 (2)
National Cancer Institute (NCI) (5) · Dana-Farber Cancer Institute (4) · M.D. Anderson Cancer Center (4) · Masonic Cancer Center, University of Minnesota (3) · Beth Israel Deaconess Medical Center (2) · Gynecologic Oncology Group (2) · Pfizer (2) · pharmaand GmbH (2) · Abramson Cancer Center at Penn Medicine (1) · Avenge Bio, Inc (1) · Bristol-Myers Squibb (1) · Cancer Research UK (1) · Columbia University (1) · Craig L Slingluff, Jr (1) · Elucida Oncology (1)
United States (50) · Canada (5) · Australia (3) · Belgium (2) · Germany (2) · Israel (2) · Italy (2) · Japan (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Austria (1) · Brazil (1) · Bulgaria (1) · Chile (1)
Melissa A. Geller, MD (2) · Amir A Jazaeri (1) · Amit Oza (1) · Amy D. Tiersten, MD (1) · Anil K. Sood, MD (1) · Brigitte E. Miller, MD (1) · Carolyn McCourt, MD (1) · Carolyn Runowicz, MD (1) · Christina M Annunziata, M.D. (1) · Craig L Slingluff, MD (1) · David Avigan, MD (1) · David H. Moore, MD (1) · David M Hyman (1)
PMID 14615449, PMID 19058838, PMID 20068097, PMID 22366591, PMID 26119093, PMID 33664128, PMID 37185961, PMID 39034053, PMID 40632975, PMID 41424175, PMID 41950571
2023 (1), N01CM00100 (1), P30CA006927 (1), P30CA008748 (1), P30CA015704 (1), P30CA016056 (1), P30CA016672 (1), P50CA083639 (1), U10CA027469 (1), U10CA032102 (1), U10CA180868 (1)